Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.67 |
| ▸ | RXRB | P28702 | 8/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.67 |
| ▸ | RXRG | P48443 | 5/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | C5 | P01031 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4328651 | 0.94 | NR4A2 (0.74) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2531133 | 0.94 | NR4A2 (0.74) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2528253 | 0.90 | RXRA (0.68) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL4334517 | 0.90 | RXRA (0.68) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2529708 | 0.90 | RXRA (0.65) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL4327039 | 0.90 | RXRA (0.65) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2529192 | 0.89 | NR4A2 (0.67) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2526068 | 0.87 | RXRA (0.61) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL4340132 | 0.87 | RXRA (0.61) | RXRARXRBNR4A2RXRGNR4A1 | |
| SCHEMBL2526835 | 0.87 | NR4A2 (0.61) | RXRARXRBNR4A2RXRGNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | claimed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | claimed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | claimed |
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | HDAC1, HDAC5, HDAC7 | RXRA 1264/4885RXRB 1916/4885NR4A2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.